{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"108-568-348-121-902","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"108-568-348-121-902","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11617,"type":"PATENT","title":"Emory University - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":6117,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8292,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: emory AND uni*
Select more for logical variants. Add to collection.
Select all patents in the collection and expand by simple families. Add to collection. Total patents: 5631
Search Applicants and Owners separately: emory AND uni*
Select more for logical variants. Add to collection.
Select all patents in the collection and expand by simple families. Add to collection. Total patents: 5631
a) administering a tubulin-targeting agent to a subject diagnosed with cancer;\n
b) measuring a sample for gene expression of checkpoint with forkhead and ring finger domains;\n
c) predicting the responsiveness of the treatment to the tubulin-targeting agent;\n
wherein heightened gene expression of checkpoint with forkhead and ring finger domains indicates an increased risk of the therapy being an ineffective treatment; and\n
d) administering an alternative chemotherapy agent to the subject."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the tubulin-targeting agent is a taxane."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein the taxane is selected from paclitaxel and docetaxel or combinations thereof."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claims 1-3, wherein the tubulin-targeting agent is administered in combination with a platinum based agent."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 4, wherein the platinum based agent is cisplatin."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claims 1-5, wherein the cancer is non-small cell lung cancer."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claims 1-6, wherein the subject is a human."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claims 1-7, wherein the sample is a tumor obtained from the subject."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 8, wherein the tumor lacks a EGFR mutation, k-ras mutation, ALK-translocations, or altered ERCC1 or RRM1 expression levels."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claims 1-9, wherein the alternative chemotherapy agent is selected from vinorelbine, etoposide, mitomycin C, gemcitabine, irinotecan, pemetrexed, gefitinib, erlotinib, lapatinib, crizotinib, and a vinca alkaloid or combinations thereof."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 10, wherein the vinca alkaloid is vinblastine, vincristine, vindesine, or vinorelbine."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of claims 1-9, the wherein the alternative chemotherapy agent is bevacizumab panitumumab, zalutumumab, nimotuzumab, matuzumab, or cetuximab."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["A method of treating cancer comprising administering an effective amount of a tubulin-targeting agent and a PARP1 inhibitor to subject in need thereof."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13, wherein the subject is diagnosed with metastatic non-small cell lung cancer."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13, wherein the tubulin-targeting agent is a taxanes."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 15, wherein the taxanes is selected from paclitaxel and docetaxel or combinations thereof."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13-16, wherein the PARP1 inhibitor is selected from iniparib, olaparib, rucaparib, veliparib, and 3-aminobenzamide, 11-methoxy-2-((4-methylpiperazin-1-yl)methyl)-4,5,6,7-tetrahydro-1H-cyclopenta[a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione, or substituted forms, or salts, or combinations thereof."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["A system for measuring and recording the gene expression of checkpoint with forkhead and ring finger domains comprising a visual device with a probe that binds to a DNA sequence or RNA sequence, or protein sequence of checkpoint with forkhead and ring finger domains and computer readable memory."],"number":18,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}